Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 39 | 2024 | 235 | 12.950 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 28 | 2023 | 165 | 7.130 |
Why?
|
| Pulmonary Fibrosis | 13 | 2024 | 123 | 5.800 |
Why?
|
| Alveolitis, Extrinsic Allergic | 9 | 2022 | 34 | 2.510 |
Why?
|
| Lung | 19 | 2024 | 1170 | 2.060 |
Why?
|
| Mucin-5B | 4 | 2022 | 11 | 1.630 |
Why?
|
| Connective Tissue Diseases | 9 | 2023 | 67 | 1.500 |
Why?
|
| Telomere | 8 | 2024 | 108 | 1.490 |
Why?
|
| Lung Transplantation | 4 | 2023 | 175 | 1.360 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2023 | 2601 | 1.320 |
Why?
|
| Pyridones | 2 | 2020 | 51 | 1.300 |
Why?
|
| Indoles | 2 | 2020 | 318 | 1.150 |
Why?
|
| Hospitalization | 5 | 2024 | 849 | 1.140 |
Why?
|
| Humans | 80 | 2024 | 86643 | 1.130 |
Why?
|
| Idiopathic Interstitial Pneumonias | 4 | 2022 | 28 | 1.120 |
Why?
|
| Disease Progression | 12 | 2023 | 1531 | 1.060 |
Why?
|
| Fibrosis | 6 | 2023 | 203 | 0.970 |
Why?
|
| Emphysema | 1 | 2023 | 22 | 0.910 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 30 | 0.910 |
Why?
|
| Cohort Studies | 13 | 2024 | 2767 | 0.900 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1673 | 0.880 |
Why?
|
| Nitric Oxide | 2 | 2022 | 278 | 0.880 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 29 | 0.860 |
Why?
|
| Immunosuppressive Agents | 7 | 2024 | 977 | 0.860 |
Why?
|
| Aged | 31 | 2023 | 18415 | 0.860 |
Why?
|
| Mediastinum | 2 | 2019 | 46 | 0.850 |
Why?
|
| Autoimmunity | 4 | 2018 | 160 | 0.850 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2023 | 104 | 0.840 |
Why?
|
| Rheumatoid Factor | 1 | 2021 | 24 | 0.840 |
Why?
|
| Mediastinal Diseases | 1 | 2021 | 21 | 0.820 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 17 | 0.820 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 29 | 0.810 |
Why?
|
| Friends | 1 | 2021 | 17 | 0.790 |
Why?
|
| Radiography, Thoracic | 3 | 2019 | 320 | 0.750 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2021 | 166 | 0.730 |
Why?
|
| Retrospective Studies | 23 | 2024 | 8489 | 0.730 |
Why?
|
| Hypertension, Pulmonary | 5 | 2022 | 346 | 0.720 |
Why?
|
| Autoimmune Diseases | 3 | 2017 | 241 | 0.720 |
Why?
|
| Male | 38 | 2024 | 40965 | 0.720 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2020 | 53 | 0.720 |
Why?
|
| Racism | 1 | 2021 | 81 | 0.710 |
Why?
|
| Mortality | 1 | 2020 | 149 | 0.700 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2020 | 219 | 0.700 |
Why?
|
| Patient Compliance | 1 | 2020 | 227 | 0.670 |
Why?
|
| Lymph Nodes | 2 | 2019 | 533 | 0.650 |
Why?
|
| Pandemics | 2 | 2021 | 740 | 0.620 |
Why?
|
| Prognosis | 9 | 2023 | 3679 | 0.620 |
Why?
|
| Female | 35 | 2024 | 44532 | 0.610 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 266 | 0.610 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.610 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 33 | 0.590 |
Why?
|
| Multiple Chronic Conditions | 1 | 2016 | 5 | 0.590 |
Why?
|
| Middle Aged | 26 | 2024 | 25028 | 0.570 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.520 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.520 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 819 | 0.510 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 150 | 0.510 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 243 | 0.490 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 103 | 0.480 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2015 | 134 | 0.470 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 639 | 0.460 |
Why?
|
| United States | 10 | 2024 | 6672 | 0.440 |
Why?
|
| Aortic Valve Stenosis | 2 | 2011 | 131 | 0.430 |
Why?
|
| Leukocytes | 3 | 2023 | 202 | 0.430 |
Why?
|
| Minority Groups | 2 | 2023 | 137 | 0.420 |
Why?
|
| Risk Assessment | 6 | 2021 | 2261 | 0.410 |
Why?
|
| Biomarkers | 4 | 2021 | 1718 | 0.410 |
Why?
|
| Respiratory Function Tests | 5 | 2023 | 136 | 0.400 |
Why?
|
| Prevalence | 7 | 2021 | 1239 | 0.390 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 2271 | 0.390 |
Why?
|
| Survival Analysis | 4 | 2019 | 1538 | 0.380 |
Why?
|
| Hypoxia | 1 | 2015 | 641 | 0.360 |
Why?
|
| Inflammation | 1 | 2015 | 920 | 0.350 |
Why?
|
| Survival Rate | 4 | 2020 | 1863 | 0.330 |
Why?
|
| Quality of Life | 1 | 2016 | 1585 | 0.330 |
Why?
|
| Proportional Hazards Models | 4 | 2023 | 859 | 0.310 |
Why?
|
| Echocardiography | 2 | 2022 | 911 | 0.300 |
Why?
|
| Cause of Death | 2 | 2019 | 277 | 0.300 |
Why?
|
| Registries | 5 | 2022 | 702 | 0.290 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 1621 | 0.280 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2207 | 0.280 |
Why?
|
| Biology | 2 | 2023 | 50 | 0.280 |
Why?
|
| Heart Failure | 1 | 2015 | 1204 | 0.270 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 937 | 0.270 |
Why?
|
| Adult | 10 | 2023 | 25648 | 0.260 |
Why?
|
| Phenotype | 3 | 2020 | 2378 | 0.240 |
Why?
|
| Scleroderma, Systemic | 1 | 2024 | 43 | 0.230 |
Why?
|
| Telomerase | 2 | 2020 | 55 | 0.230 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 25 | 0.230 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 51 | 0.230 |
Why?
|
| Pseudomonas Infections | 1 | 2023 | 95 | 0.230 |
Why?
|
| Biopsy | 4 | 2021 | 1163 | 0.220 |
Why?
|
| Age Factors | 3 | 2020 | 1851 | 0.220 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1801 | 0.220 |
Why?
|
| Shock, Septic | 1 | 2023 | 102 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2023 | 4213 | 0.210 |
Why?
|
| Risk Factors | 3 | 2021 | 5417 | 0.200 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 1019 | 0.200 |
Why?
|
| Survivors | 1 | 2023 | 226 | 0.200 |
Why?
|
| Azathioprine | 2 | 2023 | 125 | 0.200 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 28 | 0.190 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2021 | 93 | 0.190 |
Why?
|
| Health Services | 1 | 2021 | 55 | 0.190 |
Why?
|
| Respiratory Mucosa | 1 | 2021 | 88 | 0.190 |
Why?
|
| Occupational Health | 1 | 2021 | 32 | 0.190 |
Why?
|
| Hematology | 1 | 2020 | 29 | 0.190 |
Why?
|
| Vital Capacity | 4 | 2022 | 64 | 0.190 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 73 | 0.190 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 1565 | 0.190 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 379 | 0.190 |
Why?
|
| Occupational Exposure | 1 | 2021 | 80 | 0.180 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 14 | 0.180 |
Why?
|
| Mutation | 3 | 2020 | 3968 | 0.180 |
Why?
|
| Myeloblastin | 1 | 2019 | 5 | 0.180 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 267 | 0.180 |
Why?
|
| Peroxidase | 1 | 2019 | 51 | 0.180 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2019 | 21 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2024 | 263 | 0.170 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 334 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 999 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 98 | 0.160 |
Why?
|
| Influenza, Human | 1 | 2021 | 329 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 394 | 0.160 |
Why?
|
| Genotype | 2 | 2022 | 1851 | 0.160 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 59 | 0.160 |
Why?
|
| Propensity Score | 1 | 2018 | 136 | 0.160 |
Why?
|
| Anticoagulants | 1 | 2021 | 408 | 0.160 |
Why?
|
| Time Factors | 3 | 2021 | 5210 | 0.160 |
Why?
|
| Bronchiectasis | 1 | 2017 | 13 | 0.160 |
Why?
|
| Acetylcysteine | 1 | 2018 | 69 | 0.150 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2017 | 18 | 0.150 |
Why?
|
| Interleukin-5 | 1 | 2017 | 36 | 0.150 |
Why?
|
| Sex Factors | 1 | 2020 | 1054 | 0.150 |
Why?
|
| Chronic Disease | 2 | 2017 | 971 | 0.150 |
Why?
|
| Cell Differentiation | 1 | 2023 | 1458 | 0.150 |
Why?
|
| Transcriptome | 1 | 2021 | 580 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2019 | 328 | 0.150 |
Why?
|
| Acute Lung Injury | 1 | 2017 | 60 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2017 | 369 | 0.140 |
Why?
|
| Disease Management | 2 | 2016 | 327 | 0.140 |
Why?
|
| Cytokines | 2 | 2023 | 776 | 0.140 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 71 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 582 | 0.140 |
Why?
|
| Chemotactic Factors | 1 | 2015 | 14 | 0.130 |
Why?
|
| Hypoventilation | 1 | 2015 | 6 | 0.130 |
Why?
|
| STAT6 Transcription Factor | 1 | 2015 | 28 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2017 | 464 | 0.130 |
Why?
|
| Carrier Proteins | 1 | 2018 | 673 | 0.130 |
Why?
|
| Comorbidity | 2 | 2017 | 943 | 0.130 |
Why?
|
| Antigens | 1 | 2016 | 228 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 152 | 0.130 |
Why?
|
| Logistic Models | 1 | 2018 | 1186 | 0.120 |
Why?
|
| rho-Associated Kinases | 1 | 2015 | 159 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 394 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 231 | 0.120 |
Why?
|
| Genomics | 1 | 2019 | 720 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 329 | 0.120 |
Why?
|
| Sleep Wake Disorders | 1 | 2015 | 115 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2016 | 296 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 301 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2015 | 263 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6509 | 0.110 |
Why?
|
| Canada | 2 | 2023 | 204 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2015 | 447 | 0.100 |
Why?
|
| Child | 1 | 2023 | 6927 | 0.100 |
Why?
|
| Autopsy | 2 | 2021 | 116 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1036 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2019 | 7993 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2020 | 3241 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 963 | 0.080 |
Why?
|
| Antibodies, Antinuclear | 2 | 2018 | 83 | 0.080 |
Why?
|
| Cell Cycle Proteins | 2 | 2020 | 388 | 0.070 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2011 | 516 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 2262 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1805 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 860 | 0.060 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2023 | 19 | 0.060 |
Why?
|
| Rituximab | 1 | 2024 | 116 | 0.060 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 26 | 0.060 |
Why?
|
| Carbon Monoxide | 1 | 2023 | 90 | 0.060 |
Why?
|
| Australasia | 1 | 2023 | 4 | 0.060 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2023 | 48 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 299 | 0.060 |
Why?
|
| Lung Volume Measurements | 1 | 2022 | 19 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1991 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2023 | 145 | 0.050 |
Why?
|
| Europe | 1 | 2023 | 309 | 0.050 |
Why?
|
| North America | 1 | 2023 | 180 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 80 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2705 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 307 | 0.050 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2020 | 9 | 0.050 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2020 | 11 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2020 | 22 | 0.050 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 15 | 0.050 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2020 | 7 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2019 | 9 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 56 | 0.050 |
Why?
|
| Seasons | 1 | 2021 | 223 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2020 | 65 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 348 | 0.040 |
Why?
|
| Vasculitis | 1 | 2019 | 39 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 62 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 349 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2019 | 79 | 0.040 |
Why?
|
| Animals | 2 | 2017 | 26582 | 0.040 |
Why?
|
| Oxygen | 1 | 2024 | 726 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 300 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 182 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 746 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 469 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 329 | 0.040 |
Why?
|
| Bleomycin | 1 | 2017 | 98 | 0.040 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2016 | 24 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2379 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1753 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 105 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 87 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2017 | 146 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 238 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1621 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 399 | 0.030 |
Why?
|
| RNA | 1 | 2019 | 560 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1284 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 306 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 602 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 696 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2016 | 462 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 429 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 1924 | 0.030 |
Why?
|
| Chicago | 1 | 2017 | 1379 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 1351 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2818 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3092 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2232 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1920 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 5976 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 11352 | 0.010 |
Why?
|